Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €16.10 EUR
Change Today +0.248 / 1.56%
Volume 0.0
45E On Other Exchanges
As of 1:22 PM 07/28/15 All times are local (Market data is delayed by at least 15 minutes).

natera inc (45E) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/6/15 - €20.00
52 Week Low
07/28/15 - €15.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NATERA INC (45E)

Related News

No related news articles were found.

natera inc (45E) Related Businessweek News

No Related Businessweek News Found

natera inc (45E) Details

Natera, Inc., a genetic testing company, develops and commercializes non-invasive methods for analyzing deoxyribonucleic acid (DNA) in the United States and Europe. The company primarily offers Panorama, a non-invasive prenatal test for fetal chromosomal abnormalities; Horizon test; and pre-implantation genetic screening and pre-implantation genetic diagnosis tests under the Spectrum brand to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization. It also provides products of conception testing under the Anora brand to analyze fetal chromosomes to understand the cause of miscarriage; non-invasive paternity testing products to determine paternity by analyzing the fragments of fetal DNA in a pregnant mother's blood and a blood sample from the alleged father; and high throughput carrier screening to determine the risk of passing severe genetic diseases on to offspring. Natera sells its tests directly and partner with other clinical laboratories to distribute its tests. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.

674 Employees
Last Reported Date: 07/2/15
Founded in 2003

natera inc (45E) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $283.0K
Chief Financial Officer
Total Annual Compensation: $294.4K
Chief Technology Officer and Director
Total Annual Compensation: $283.0K
Compensation as of Fiscal Year 2014.

natera inc (45E) Key Developments

Natera, Inc.(NasdaqGS:NTRA) added to NASDAQ Composite Index

Natera, Inc. has been added to Nasdaq Composite Index.

Natera Seeks Acquisitions

Natera, Inc. will consider acquisitions. Natera has filed an IPO in the amount of $100 million and will use a portion of the net proceeds received for acquisitions of complementary businesses, technologies or other assets. However, we have no current understandings, agreements or commitments for any material acquisitions.

LifeLabs and Natera Announce Agreement for Panorama™ Non-Invasive Prenatal Test (NIPT) in Canada

LifeLabs Medical Laboratory Services and Natera, Inc. announced a new agreement that gives LifeLabs the rights to perform non-invasive prenatal testing (NIPT) in Canada using Natera technology. Pregnant women and their healthcare professionals will receive faster information about their fetus using world-class technology delivered through a Canadian based laboratory. This announcement builds on the LifeLabs-Natera partnership established in 2013 which resulted in LifeLabs becoming the first Canadian distributor of Panorama. This marks an important step in bringing meaningful, clinically relevant genetic information to Canadians while building next-generation genetic testing expertise and capacity in Canada. Panorama is a safe and simple way for expectant mothers to learn about the health of their baby without an invasive diagnostic procedure. Panorama uses a simple blood draw from the mother to examine cell-free DNA found in maternal blood originating from both mother and fetus to screen for chromosome abnormalities, including trisomy 21 (Down syndrome), trisomy 18 (Edwards syndrome), trisomy 13 (Patau syndrome), monosomy X (Turner syndrome), and triploidy. Panorama is also able to screen for five clinically relevant microdeletions, conditions that are the result of missing pieces of DNA on specific chromosomes. The test can be performed as early as nine weeks of gestation without any risk to the fetus.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
45E:GR €16.10 EUR +0.248

45E Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocept Inc $2.47 USD -0.01
Fluidigm Corp $21.17 USD -0.70
Laboratory Corp of America Holdings $122.21 USD +0.50
Sequenom Inc $2.96 USD +0.08
Trovagene Inc $8.35 USD -0.17
View Industry Companies

Industry Analysis


Industry Average

Valuation 45E Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 3.7x
Price/Book 11.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NATERA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at